Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.39 |
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12944195 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL29579452 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL13110590 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL19731720 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL2734925 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL12094377 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL13830646 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| Trifluoroacetic Acid SCHEMBL31096968 | 0.96 | PTPN1 (0.43) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL15088221 | 0.96 | HTR2A (0.40) | HTR2APTPN1SSTR3SIRT2SIRT1 | |
| SCHEMBL13311064 | 0.94 | FURIN (0.39) | HTR2APTPN1FURINSSTR3SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250342-A2 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2025-08-07 | — | — | US | claimed |
| CN-118047832-A | Anti-MET antibodies that bind MET, bispecific antigen binding molecules, and methods of use thereof | 瑞泽恩制药公司 | 2024-05-17 | — | — | CN | claimed |
| US-20230416376-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2023-12-28 | — | — | US | claimed |
| US-20260144886-A1 | TARGETED DRUG CONJUGATE, MEDICINE INCLUDING SAME, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12624109-B2 | αv-integrin targeted small molecule drug conjugates | TARGETTHERA LLC (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2026087536-A1 | METHODS OF USING HOMOTAURINE AND ANALOGS THEREOF FOR THE TREATMENT OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST INDUCED GASTROINTESTINAL SIDE EFFECTS | UNIVERSITY OF TARTU (EE) | 2026-04-30 | — | — | WO | disclosed |
| US-20260097129-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING DRUG AND ANTIBODY SPECIFICALLY BINDING TO GRP94 OR ANTIGEN-BINDING FRAGMENT THEREOF | UNIV KOOKMIN IND ACAD COOP FOUND (KR) | 2026-04-09 | — | — | US | disclosed |
| EP-4721767-A1 | ANTI-B7-H3 ANTIBODY OR FRAGMENT THEREOF, AND ANTIBODY DRUG CONJUGATE TARGETING B7-H3 | Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12570610-B2 | Macromolecule-supported aminobenzazepine compounds | BOLT BIOTHERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-121586588-A | Targeted drug complexes, and pharmaceutical products and compounds comprising the same | 富士胶片株式会社 | 2026-02-27 | — | — | CN | disclosed |
| US-20260053939-A1 | Combination Therapy for Cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-02-26 | — | — | US | disclosed |
| CN-109790178-B | Novel cytotoxic agents and conjugates thereof | 宝力泰锐克斯有限公司 | 2022-05-03 | — | — | CN | disclosed |
| WO-2022086853-A1 | STAR POLYMER DRUG CONJUGATES | AVIDEA TECHNOLOGIES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3980423-A1 | 5H-PYRROLO[3,2-D]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF | Sutro Biopharma, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3980080-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | Sutro Biopharma, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-114272389-A | Eribulin-based antibody-drug conjugates and methods of use | 卫材研究发展管理有限公司 | 2022-04-05 | — | — | CN | disclosed |
| WO-2022067224-A1 | COMPOSITION AND USE OF ALTERNATIVELY FORMATTED ANTI-MESOTHELIN ANTIBODIES FOR THE TREATMENT OF CANCER | Navrogen, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |
| CN-114191563-A | Eribulin-based antibody-drug conjugates and methods of use | 卫材研究发展管理有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114191428-A | Eribulin-based antibody-drug conjugates and methods of use | 卫材研究发展管理有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220072137-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATES AND ITS USE | REMEGEN CO., LTD. (CN) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053939-A1 | Combination Therapy for Cancer | BCL6, PSMB6, PDCD6 | HTR2A 4727/4885PTPN1 443/4885FURIN 4825/4885 |
| US-20260097129-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING DRUG AND ANTIBODY SPECIFICALLY BINDING TO GRP94 OR ANTIGEN-BINDING FRAGMENT THEREOF | FCGR2A, HACD3, FCER2 | HTR2A 2807/4885PTPN1 2027/4885FURIN 4645/4885 |
| US-20250250342-A2 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | MET, HGF, HGFAC | HTR2A 1559/4885PTPN1 598/4885FURIN 2633/4885 |
| US-20230416376-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | MET, HGF, HGFAC | HTR2A 1559/4885PTPN1 598/4885FURIN 2633/4885 |
| US-12624109-B2 | αv-integrin targeted small molecule drug conjugates | ITGA1, ITGB1, ITGA2 | HTR2A 3448/4885PTPN1 2335/4885FURIN 3063/4885 |
| US-12570610-B2 | Macromolecule-supported aminobenzazepine compounds | BCL6, CLTB, MET | HTR2A 1107/4885PTPN1 3340/4885FURIN 1525/4885 |
| US-20220072137-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATES AND ITS USE | PA2G4, IGSF11, FCGRT | HTR2A 3844/4885PTPN1 1681/4885FURIN 1746/4885 |
| US-20260144886-A1 | TARGETED DRUG CONJUGATE, MEDICINE INCLUDING SAME, AND COMPOUND | SLC43A1, SLC7A1, SLC10A1 | HTR2A 2598/4885PTPN1 466/4885FURIN 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.